Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 104.0% in May

Context Therapeutics Inc. (NASDAQ:CNTXGet Rating) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 91,000 shares, an increase of 104.0% from the May 15th total of 44,600 shares. Based on an average daily trading volume, of 374,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.7% of the company’s shares are short sold.

Shares of Context Therapeutics stock opened at $1.91 on Friday. Context Therapeutics has a one year low of $1.27 and a one year high of $10.87. The business’s 50 day moving average price is $1.80 and its 200 day moving average price is $2.41.

A number of institutional investors have recently made changes to their positions in CNTX. BlackRock Inc. purchased a new position in Context Therapeutics during the fourth quarter worth approximately $31,000. QCM Cayman Ltd. purchased a new position in Context Therapeutics during the fourth quarter worth approximately $37,000. swisspartners Ltd. purchased a new position in Context Therapeutics during the fourth quarter worth approximately $114,000. Virtu Financial LLC purchased a new stake in Context Therapeutics in the fourth quarter valued at $142,000. Finally, Renaissance Technologies LLC purchased a new stake in Context Therapeutics in the fourth quarter valued at $172,000. Hedge funds and other institutional investors own 28.51% of the company’s stock.

Context Therapeutics Company Profile (Get Rating)

Context Therapeutics Inc, a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.

Further Reading

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.